The Indian government has announced several initiatives in the Union Budget 2025-26 to strengthen cancer care and improve treatment accessibility. One of the major highlights is the plan to establish 200 cancer daycare centers across district hospitals over the next three years. This move aims to enhance early intervention and reduce the burden on larger medical institutions.
To further reduce treatment costs, the government has exempted basic customs duty on 36 life-saving drugs used in cancer and rare disease treatment. Both public and private sectors are increasingly prioritising cancer care. To support such initiatives Biozenta has set up an Active Pharmaceutical Ingredient (API) manufacturing plant to meet critical production demands. This initiative is expected to enhance self-reliance in manufacturing, helping to stabilize production costs and ensure consistent drug availability.
India’s role in the global oncology sector has expanded significantly in recent years. The country’s strong medical infrastructure, skilled professionals, and relatively lower treatment costs have positioned it as a key provider of cost-effective cancer care solutions.
To sustain this growth, stakeholders are being encouraged to invest in research and development (R&D) capabilities, which could help India emerge as a leader in specialized therapy areas. Industry experts have suggested that introducing government-backed incentives for innovative organizations could further boost R&D efforts. Biozenta has already taken steps in this direction by establishing a DSIR-approved R&D lab dedicated to developing new oncology drugs. The lab is staffed with experienced scientists and researchers committed to advancing medical innovation. Biozenta has also successfully collaborated with partners on technology transfer projects, showcasing its expertise in tackling complex oncology challenges.
The Indian government’s efforts to support medical exports, improve regulatory frameworks, and maintain quality standards have further strengthened India’s position in the global oncology market. Initiatives like Ayushman Bharat and the National Cancer Grid have also played a key role in enhancing cancer care services nationwide.
As global cancer rates continue to rise, India’s ability to deliver affordable and accessible treatment will remain vital in addressing this growing healthcare challenge.
In the realm of drug delivery innovations, nanoparticles and liposomal formulations are gaining attention for their ability to improve bioavailability, ensure controlled release, and enable targeted delivery. While these systems offer significant benefits, challenges such as manufacturing complexities, high costs, and regulatory concerns remain. Nevertheless, they hold immense potential, particularly for drugs with poor solubility or those requiring precise targeting.
Biozenta’s state-of-the-art manufacturing facility is well-equipped to produce liposomal oncology finished-dose formulations, including Amphotericin B, Peg Asparaginase, and Daunorubicin. Additionally, its nanoparticle-based product range includes Triptorelin, Paclitaxel, Leuprolide, and Goserelin, further strengthening Biozenta’s role in advanced cancer care solutions.
(DISCLAIMER: The views expressed are solely of the author and ETHealthworld.com does not necessarily subscribe to it. ETHealthworld.com shall not be responsible for any damage caused to any person/organisation directly or indirectly)
